|
|
|||
Description:Long chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) catalyzes the third step in the mitochondrial beta-oxidation spiral. LCHAD deficiency is usually evident in the neonatal period or in early childhood after a period of fasting or viral illness. Clinical manifestations include (1) Reye-like syndrome with hypoglycemia, fatty liver, and coma; (2) sudden unexplained death; (3) dilated or hypertrophic cardiomyopathy; or (4) skeletal myopathy. Isolated LCHAD deficiency in newborns may be associated with severe maternal illness occurring during pregnancies with affected fetuses. These maternal illnesses include the acute fatty liver of pregnancy (AFLP) syndrome; hypertension or hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome, and hyperemesis gravidarum. Target analysis for the two common mutations (1528G>C and 1132C>T) and sequence analysis of the entire coding region of the long-chain hydroxyacyl-CoA dehydrogenase (HADHA) gene are available on a clinical basis at the Medical Genetics Laboratories at Baylor College of Medicine. Reasons for Referral:
Testing Methodology:Full
Sequencing: PCR amplification of all exons contained
in the LCHAD gene coding region will be performed on patients genomic DNA.
Direct sequencing of the amplification products is performed in both the
forward and reverse directions using automated fluorescence dideoxy sequencing
methods.
Specimen Requirements:Blood: EDTA (purple-top) tubes: Adult: 14 cc; Child: 6 cc; Infant: 2-3 cc Turnaround Time:Full Sequencing: 4
weeks CPT Codes and Prices:Full Sequencing: 83904x40,
83898x20, 83912, 83891, 83894x2 Shipping InformationForms:>> Gene Sequencing Requisition Test Codes:Full Sequencing: 3120 |